Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 7439698, 8 pages
Research Article

Identification of Circulating Long Noncoding RNA Linc00152 as a Novel Biomarker for Diagnosis and Monitoring of Non-Small-Cell Lung Cancer

1Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
2Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
3School of Laboratory Medicine, Hubei University of Traditional Chinese Medicine, Wuhan, Hubei, China

Correspondence should be addressed to Jiancheng Tu and Yong Ning

Received 4 June 2017; Revised 12 July 2017; Accepted 27 July 2017; Published 19 November 2017

Academic Editor: Olav Lapaire

Copyright © 2017 Nandi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Long noncoding RNAs (lncRNAs) have been reported to play vital roles in non-small-cell lung cancer (NSCLC). Recently, long noncoding RNA Linc00152 has been reported to play important roles in various cancers. In this study, our aim was to investigate its expression pattern and clinical significance and further evaluate its diagnostic value for NSCLC. Methods. The levels of Linc00152 were detected in NSCLC tissues and plasma samples by quantitative real-time PCR (qRT-PCR). Receiver operating characteristic (ROC) curves were depicted to evaluate the diagnostic value. Results. We found that Linc00152 levels were upregulated in both NSCLC tissues and plasma samples. Plasma Linc00152 levels were significantly lower in postoperative samples than in preoperative samples. Besides, high Linc00152 expression was significantly correlated with tumor size (, ) and tumor stage (, ). The ROC curves indicated that plasma Linc00152 has high diagnostic accuracy for NSCLC, and the area under curve (AUC) for NSCLC versus healthy was 0.816 (95% CI: 0.757–0.875). Moreover, we found that the combination of Linc00152 and CEA could provide a more powerful diagnosis efficiency than Linc00152 or CEA alone (AUC = 0.881, 95% CI: 0.836–0.926). Conclusions. Plasma Linc00152 could serve as a promising biomarker for diagnosing and monitoring NSCLC.